|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
JP2005500061A
(ja)
|
2001-08-20 |
2005-01-06 |
ザ スクリップス リサーチ インスティテュート |
Ｃｎｎについての亜鉛フィンガー結合ドメイン
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
MX2014001222A
(es)
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
DK2956175T3
(da)
|
2013-02-15 |
2017-11-27 |
Univ California |
Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
US10934346B2
(en)
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
CA2941004A1
(en)
|
2014-03-04 |
2015-09-11 |
Peter Flynn |
Improved reprogramming methods and cell culture platforms
|
|
CA2945388A1
(en)
*
|
2014-04-23 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) for use in therapy and methods for making the same
|
|
AU2015312117A1
(en)
|
2014-09-02 |
2017-03-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
|
|
WO2016126608A1
(en)
*
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
JP2018510652A
(ja)
*
|
2015-03-18 |
2018-04-19 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
KR20180083874A
(ko)
*
|
2015-11-04 |
2018-07-23 |
사울 제이. 프라이스맨 |
Her2를 표적화하는 키메라 항원 수용체
|
|
US20170166877A1
(en)
|
2015-12-14 |
2017-06-15 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
JP7554670B2
(ja)
|
2017-10-11 |
2024-09-20 |
フェイト セラピューティクス，インコーポレイテッド |
一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング
|
|
KR102774451B1
(ko)
*
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
JP2021505131A
(ja)
|
2017-12-08 |
2021-02-18 |
フェイト セラピューティクス，インコーポレイテッド |
増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法
|
|
IL316257A
(en)
|
2017-12-22 |
2024-12-01 |
Fate Therapeutics Inc |
Enhanced immune effector cells and use thereof
|
|
SG10201801219VA
(en)
*
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
|
KR102817092B1
(ko)
|
2018-03-29 |
2025-06-09 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 면역 효과기 세포 및 이의 용도
|
|
WO2020018620A1
(en)
|
2018-07-17 |
2020-01-23 |
The Regents Of The University Of California |
Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
IL286482B2
(en)
|
2019-03-21 |
2025-01-01 |
Gamida Cell Ltd |
Cultured NK cell fractions for use in combination therapy
|
|
CN113993902B
(zh)
*
|
2019-03-22 |
2025-03-14 |
瑟缇斯治疗私人有限公司 |
抗her2结合分子
|
|
CN114258429A
(zh)
|
2019-07-17 |
2022-03-29 |
菲特治疗公司 |
免疫效应细胞工程化和其用途
|
|
MX2022003414A
(es)
|
2019-09-25 |
2022-04-18 |
Fate Therapeutics Inc |
Celulas efectoras con multiples objetivos y uso de las mismas.
|
|
EP4041759A4
(en)
|
2019-10-07 |
2023-12-20 |
Fate Therapeutics, Inc. |
IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
|
|
EP4045539A4
(en)
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
US20230016034A1
(en)
|
2019-12-06 |
2023-01-19 |
Fate Therapeutics, Inc. |
ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS
|
|
US20230072955A1
(en)
*
|
2020-01-23 |
2023-03-09 |
Exuma Biotech Corp |
Chimeric antigen receptors to her2 and methods of use thereof
|
|
EP4153635A4
(en)
|
2020-05-22 |
2024-06-26 |
GC Cell Corporation |
ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
|
|
AU2021372975A1
(en)
|
2020-11-04 |
2023-06-15 |
Fate Therapeutics, Inc. |
Engineered ipsc and persistent immune effector cells
|
|
EP4240832A4
(en)
|
2020-11-04 |
2025-01-01 |
Fate Therapeutics, Inc. |
Engineered ipsc and immune effector cells for heterogenous tumor control
|
|
CN112391414A
(zh)
*
|
2020-11-17 |
2021-02-23 |
中国医学科学院基础医学研究所 |
一种靶向her2的car-t表达载体及其构建和应用
|
|
TW202546008A
(zh)
*
|
2020-11-30 |
2025-12-01 |
日商小野藥品工業股份有限公司 |
Her2標靶藥物
|
|
US20250222029A1
(en)
|
2022-04-08 |
2025-07-10 |
Fate Therapeutics, Inc. |
Chimeric antigen receptor for tumor targeting
|